Pfizer, BioNTech Choose Coronavirus Vaccine Candidate to Advance to Phase 2/3 Trial

Two companies considered to be advanced in their pursuit of a coronavirus vaccine, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), have selected one candidate for advancement to a phase 2/3 clinical study. The two companies, which are collaborating on the vaccine effort, said Monday in a joint press release that they have chosen BNT162b2, one of four candidates they were testing.